Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

NCT03326258 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped The study itself was Disapproved on 04/20/2018 and will not be moving forward.

Conditions

Advanced Malignant Solid Neoplasm
Estrogen Receptor Negative
GPNMB Positive
HER2/Neu Negative
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Progesterone Receptor Negative
Stage III Breast Cancer AJCC v7
Stage III Cutaneous Melanoma AJCC v7
Stage III Uveal Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IV Uveal Melanoma AJCC v7
Triple-Negative Breast Carcinoma
Unresectable Solid Neoplasm

Interventions

DRUG: Glembatumumab Vedotin
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)